Madrigal Pharmaceuticals Inc
Open
SectorGezondheidszorg
503.88 2.82
Overzicht
Wijziging aandelenprijs
24u
Min
488.93
Max
506.47
Inkomsten | -36M -94M |
|---|---|
Verkoop | -9.7M 311M |
EPS | -1.38 |
Winstmarge | -30.318 |
Werknemers | 915 |
EBITDA | -43M -93M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +34.95% upside |
Volgende Winsten | 4 aug 2026 |
|---|
Marktkapitalisatie | -1.2B 11B |
|---|---|
Vorige openingsprijs | 501.06 |
Vorige sluitingsprijs | 503.88 |
Nieuwssentiment
By Acuity
47%
53%
153 / 342 Rangschikking in Healthcare
Madrigal Pharmaceuticals Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
